[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alzheimer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alzheimer":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,49,83,111],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":4},"100648445","telerehabilitation-in-alzheimers-disease-100648445",false,"NCT07722169","Telerehabilitation in Alzheimer's Disease","Home-based Virtual Reality Cognitive Training as an add-on to Telerehabilitation in Alzheimer's Disease: Validation of a Protocol to Slow Down Cognitive Decline and Reduce Caregivers' Burden","VRTAD","Inclusion criteria for patients with Alzheimer's disease (AD):\n\n* Age between 50 and 90 years.\n* Diagnosis of Alzheimer's disease according to established diagnostic criteria.\n* Mini-Mental State Examination (MMSE) score between 18 and 24.\n* Stable pharmacological treatment for at least 3 months before enrolment.\n* Ability and willingness to provide written informed consent.\n\nInclusion criteria for caregivers:\n\n* Age ≥18 years.\n* Availability to assist the patient throughout the study.\n* Ability and willingness to provide written informed consent.\n\nExclusion criteria for patients with Alzheimer's disease (AD):\n\n* Refusal or inability to provide written informed consent.\n* History of psychiatric disorders.\n* Significant cerebrovascular disease.\n* Severe visual or hearing impairment that could interfere with study procedures.\n* Psychosis.\n* Major depressive disorder.\n* Alcohol or substance abuse.\n* Use of psychotropic medications that may interfere with neuropsychological assessment or study treatment.\n* Concurrent participation in another interventional pharmacological clinical trial.\n* Any contraindication to undergoing EEG recording.\n\nExclusion criteria for caregivers:\n\n* Refusal or inability to provide written informed consent.\n* History of psychiatric disorders.\n* Major depressive disorder.\n* Alcohol or substance abuse.\n* Use of psychotropic medications that may interfere with neuropsychological assessment.",true,"ALL","50 Years","90 Years",{"count":22,"type":23},48,"ESTIMATED","INTERVENTIONAL",[26],"NA","Telemedicine has developed rapidly during the COVID-19 pandemic and is now integrated into the clinical practice of many hospitals. Telemedicine offers many advantages, and even after the end of the pandemic, many patients still choose to undergo healthcare visits remotely. However, the rapid expansion of telemedicine may be associated with the risk of providing patients with unvalidated and uncontrolled telehealth solutions, potentially negatively impacting their health.\n\nIn this study, the researchers aim to investigate the effectiveness of remote cognitive training in patients with mild-to-moderate Alzheimer's disease (AD) using tablets equipped with virtual reality-based cognitive exercises. The investigators also aim to evaluate the impact of online supervision of cognitive training by a neuropsychologist and to compare the costs and burden of home-based versus hospital-based cognitive training in patients with AD. This project will define the optimal modalities for cognitive telerehabilitation to ensure validated protocols for the continuity of care in AD.",[29],"Alzheimer",[31,32,33,34,35,36],"cognitive training","telerehabilitation","virtual reality","Alzheimer's disease","Cognitive functions","caregiver","NOT_YET_RECRUITING","2026-07-30",{"date":40,"type":41},"2026-08-03","ACTUAL",{"date":43,"type":23},"2026-10",{"date":45,"type":23},"2029-10",{"name":47,"class":48},"IRCCS San Raffaele","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100646366","phase-1-low-dose-radiotherapy-for-alzheimers-disease-100646366","NCT07693140","Low-Dose Radiotherapy for Alzheimer's Disease","Low-Dose Radiotherapy for Alzheimer's Disease: A Phase I\u002FII Open-Label Feasibility and Safety Study (LDRT-MIND Trial)","LDRT-MIND","Inclusion Criteria:\n\n1. Age ≥50 years at time of enrollment\n2. Externally confirmed diagnosis by a neurologist or geriatric psychiatrist (at Renaissance Institute, collaborating neurologist Dr. Sherif Makar, MD of Charis Neurology is available for diagnostic consultation) of one of the following: a. Alzheimer's disease (per NIA-AA 2011 or 2018 criteria) b. Frontotemporal dementia with documented inflammatory features c. Dementia with Lewy bodies with elevated inflammatory CSF markers d. Other neurodegenerative dementia with confirmed inflammatory component (elevated CSF IL-6, IL-1β, or TNF-α; or neuroimaging evidence of neuroinflammation)\n3. MoCA score 10-25 at baseline screening (moderate-to-mild cognitive impairment range)\n4. Karnofsky Performance Status (KPS) ≥60 or ECOG Performance Status ≤2\n5. Medically stable and capable of receiving radiation therapy as assessed by the treating radiation oncologist\n6. Reliable caregiver or informant able to accompany the patient to ≥80% of scheduled visits\n7. Written informed consent from patient (if decision-making capacity is preserved) and\u002For legally authorized representative (LAR); caregiver co-consent required\n8. Life expectancy ≥18 months in the opinion of the treating physician\n9. Ability and willingness to comply with monthly clinic visits for the 12-month maintenance period\n\n   \\--------------------------------------------------------------------------------------\n\nExclusion Criteria:\n\n1. Prior whole brain or partial brain radiotherapy of any dose at any time\n2. Active systemic malignancy requiring concurrent oncologic treatment\n3. Implanted device contraindicated with radiation therapy (pacemaker, cochlear implant, deep brain stimulator, or equivalent)\n4. Brain MRI demonstrating any of the following: (a) more than 4 cerebral microhemorrhages on susceptibility-weighted imaging (SWI) or gradient echo (GRE) sequences; (b) more than 1 area of superficial cortical siderosis; (c) severe white matter disease (Fazekas grade 3); or (d) any macrohemorrhage or hemosiderin-stained lesion \\>10 mm. These thresholds are adapted from established AD trial imaging exclusion criteria to minimize enrollment of patients with advanced cerebrovascular disease or pre-existing hemorrhagic risk factors.\n5. Known active cerebral amyloid angiopathy-related inflammation (CAA-ri) or amyloid-related beta-angiitis (ABRA), whether confirmed by biopsy, CSF analysis, or neuroimaging features consistent with active leptomeningeal or parenchymal amyloid-related inflammation\n6. Active autoimmune encephalitis in acute phase (patients in stable chronic phase are eligible)\n7. Uncontrolled systemic infection or active sepsis at enrollment\n8. Severe psychiatric comorbidity (active psychosis, active suicidal ideation) impairing protocol compliance or safety assessment\n9. Concurrent enrollment in another interventional trial targeting cognitive decline or neuroinflammation\n10. Pregnancy or lactation; women of childbearing potential must use adequate contraception\n11. Inability to lie flat and still for radiation delivery (approximately 10-15 minutes per session)\n12. MoCA \\\u003C10 at baseline screening (severe dementia; insufficient cognitive range for endpoint assessment)",{"count":58,"type":23},50,[60,61],"PHASE1","PHASE2","To evaluate the safety and tolerability of low-dose whole brain radiotherapy (WBRT) delivered as an induction course of 0.3 Gy × 10 fractions (3.0 Gy total) followed by 12 months of monthly maintenance LDRT (0.3 Gy × 10 fractions; 3.0 Gy total) in patients with Alzheimer's disease or dementia with inflammatory components",[64,65,66,29,67],"Alzheimer Dementia","Dementia","Alzheimer Dementia (AD)","Alzheimer s Disease",[69,70,71,65,29],"LDRT","Low-dose radiotherapy","Low-dose radiation therapy","RECRUITING","2026-07-03",{"date":75,"type":41},"2026-07-09",{"date":77,"type":23},"2026-07-15",{"date":79,"type":23},"2029-05-21",{"name":81,"class":48},"Evan Thomas",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":17,"sex":18,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":82},"100645158","alzevit-nationwide-digital-apoe-4-cohort-for-early-alzheimers-disease-prevention-and-trial-readiness-100645158","NCT07679906","ALZEVIT: Nationwide Digital APOE ε4 Cohort for Early Alzheimer's Disease Prevention and Trial Readiness","ALZEVIT: A Nationwide Decentralized Digital Cohort for Population APOE Genotyping, Longitudinal Characterization of APOE ε4\u002Fε4 Trajectories, and Trial-readiness for Precision Prevention in Early Alzheimer's Disease","ALZEVIT","Inclusion Criteria:\n\n* Participants who sign the electronic Informed Consent form.\n* Adults aged over 45 years old (inclusive) at the time of consent.\n* Participants residing in France.\n* Participants able to read and understand the study information in French or with the help of a legal representative.\n* Participants are capable of electronically signing the consent form.\n* Participants affiliated with the French national health insurance system.\n* Participants with access to the internet and a valid email address.\n* Participants can self-collect and return a saliva sample using a provided kit (ORAcollect® Dx device).\n\nExclusion Criteria:\n\n* Participants who do not sign the Informed Consent form.\n* Participants who are unable to read or understand French.\n* Participants younger than 45 years at the time of consent.\n* Participants with known cognitive impairments, severe dementia, or psychiatric conditions that prevent informed consent.\n* Participants with a documented substance use disorder (alcohol or drug dependence) within the past 24 months.\n* Participants who cannot be reliably contacted by email or phone.\n* Participants previously enrolled in the ALZEVIT study or its pilot phase.\n* Participants who are legally protected adults or under guardianship, curatorship, or judicial\u002Fadministrative custody.\n* Participants whose physical condition does not allow them to perform the tasks required by the study.\n* Participants who, in the judgment of the Investigator, are unlikely to comply with study procedures.\n* Participants who are study staff (investigators, sub-investigators, coordinators, assistants) or their immediate family members.\n* Participants who are incarcerated or deprived of liberty by judicial or administrative decision.\n* Participants with any disease or condition that, in the opinion of the Investigator, would compromise participation or safety.","45 Years",{"count":93,"type":23},50000,"OBSERVATIONAL","ALZEVIT is a nationwide, decentralized, digital-first cohort study in France designed to establish a large-scale Apolipoprotein E (APOE) genotyping registry and enable precision prevention strategies for Alzheimer's disease (AD). Sponsored by Firalis SA and conducted in collaboration with French memory centers, it addresses the need for early identification of individuals at high genetic risk, particularly APOE ε4 carriers and ε4\u002Fε4 homozygotes, in the context of emerging disease-modifying therapies most effective in preclinical or early disease stages.\n\nUsing an online recruitment platform, participants aged ≥45 years provide electronic informed consent and self-collected saliva samples via home collection kits for centralized APOE genotyping using the APO-Easy® assay, compliant with EU IVDR and US FDA requirements. Data are stored in a secure registry compliant with GDPR.\n\nPhase A (0-18 months) will enroll 50,000 participants to determine national APOE genotype distribution, identify high-risk individuals, and evaluate feasibility of large-scale digital genetic screening, with longitudinal online follow-up including cognitive and risk factor assessments.\n\nPhase B (12-24 months) includes detailed phenotyping of \\~2,350 selected participants across all APOE genotypes, including \\~750 ε4\u002Fε4 homozygotes. Participants undergo clinical evaluation, MRI, cognitive testing, and multi-omics biomarker profiling (genomics, proteomics, metabolomics, environmental exposure), conducted at memory centers or via telemedicine.\n\nThe study classifies participants along the cognitive continuum, including cognitively normal individuals, preclinical AD, mild cognitive impairment (MCI), and mild or moderate AD, to identify genotype-specific trajectories and modifiable risk and resilience factors. ALZEVIT aims to establish a scalable national infrastructure linking genetic stratification with longitudinal biomarker and clinical data to support prevention trials, improve understanding of APOE-related heterogeneity, and advance precision medicine for Alzheimer's disease.",[29],[98,99,100],"APOE ε4\u002Fε4","Genetic Risk Profiling","Alzheimer's Disease","2026-06-25",{"date":103,"type":41},"2026-07-01",{"date":105,"type":23},"2026-07",{"date":107,"type":23},"2028-05-01",{"name":109,"class":110},"Firalis SA","INDUSTRY",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":18,"minAge":118,"maxAge":4,"enrollmentInfo":119,"targetDuration":121,"studyType":94,"phases":4,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100629347","assessment-of-malnutrition-in-hospitalized-patients-a-quasi-study-100629347","NCT07473492","Assessment of Malnutrition in Hospitalized Patients: a Quasi Study","AMMRP","Inclusion Criteria:\n\n* Age: Adult patients aged $\\\\ge$ 18 years.Setting: Patients admitted to the Medicine, Surgery, or Neurology Intensive Care Unit (ICU) wards at Al-Basrah Teaching Hospital or Al-Fayhaa General Hospital.Duration of Stay: Patients who have been hospitalized for a minimum of 48 hours (to ensure a baseline for malnutrition screening and medication review).Clinical Conditions: Patients with various primary diagnoses, including specific subgroups with Chronic Obstructive Pulmonary Disease (COPD) and Alzheimer's Disease.Informed Consent: Patients or their legal guardians (especially for those in the ICU or with cognitive impairment) who provide written or verbal informed consent.\n\nExclusion Criteria:\n\n* Maternity\u002FObstetrics: Pregnant or lactating women, as nutritional requirements and physiological BMI changes differ from the general adult population.\n\nTerminal Illness: Patients in end-of-life or palliative care where nutritional intervention is no longer a clinical goal.\n\nIncomplete Records: Patients with missing medical or medication charts that prevent the accurate identification of Medication-Related Problems (MRPs).\n\nShort Stay: Patients planned for discharge or transfer within less than 48 hours of admission.\n\nPsychiatric Disorders: Patients with primary psychiatric diagnoses that may interfere with the ability to conduct nutritional assessments (unless a guardian is present).","18 Years",{"count":120,"type":23},300,"1 Month","Malnutrition among hospitalized patients is a critical, yet often overlooked, public health issue associated with increased complications, longer hospital stays, higher mortality, and greater healthcare costs. In Iraq, factors such as dietary patterns, the burden of chronic diseases, and healthcare constraints may increase the risk of hospital-acquired malnutrition. Current standard care may not include systematic nutritional screening or protocol-driven support. This trial aims to test whether implementing an individualized nutritional support program can improve clinical outcomes for at-risk medical inpatients in Iraqi hospitals, building upon evidence from international studies",[124,29,67],"COPD , Neurology , ICU",[126,127],"Hospital Malnutrition , Nutritional Risk Screening ,GLIM Criteria","Medication-Related Problems (MRPs","2026-03-11",{"date":130,"type":41},"2026-03-16",{"date":132,"type":23},"2026-04-01",{"date":134,"type":23},"2026-09-01",{"name":136,"class":48},"AlFayhaa General Hospital"]